Navigation Links
InterMune to Present at Deutsche Bank Biotech Confab
Date:12/11/2009

BRISBANE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Chief Medical Officer of InterMune, will present at the 2009 DB-Biotech Boston Confab on December 15, 2009 at 9:30 a.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and has submitted a New Drug Application (NDA) to the FDA. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (RG7227) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

SOURCE InterMune, Inc.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
2. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
3. InterMune to Present at JMP Securities Conference
4. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
5. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
6. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
7. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
10. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
11. InterMune Announces Progress on Pirfenidone in IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking one ... with one on her shoulder and one on her arm. But she got to ... years of mitral valve prolapse. , The valves of the heart wouldn’t close properly ...
(Date:5/3/2016)... Pasadena, CA (PRWEB) , ... May 03, 2016 ... ... tuition-free, accredited American online university, has announced today the launch of its Associates ... Nobel Laureate and President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Boston Children’s Hospital ... rehearse tough medical situations or practice tricky or rare procedures in an environment that ... the SIM Center is also available to inventors and “hackers” to develop and test ...
(Date:5/3/2016)... ... 03, 2016 , ... Park Cities Pet Sitter has openings for both full-time ... 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. ... Plano, Preston Hollow and Park Cities areas of the Metroplex. Candidates must love ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 ... ... solutions for the healthcare industry, announced today that Legacy Health is expanding its ... Efficient Works platform), after a highly successful initial proof of concept. The Portland, ...
Breaking Medicine News(10 mins):